Skip to content

Exelixis EXEL Price / book

Price / book at other companies

Eli Lilly logo
Eli LillyLLY
26.3×-20.7×
Pfizer logo
PfizerPFE
1.8×+0.2×
Summit Therapeutics logo
Summit TherapeuticsSMMT
26.9×-14.4×
Incyte logo
IncyteINCY
3.3×+0.1×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
25.2×+15.2×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
3.9×-0.5×

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Calculated from Exelixis’s reported figures.

Based on the most recent quarter.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's price / book?
Exelixis (EXEL) reported price / book of 5.8× in Q1 2026.
How has Exelixis's price / book changed year-over-year?
Exelixis's price / book increased by 21.2% year-over-year, from 4.8× to 5.8×.
What is the long-term trend for Exelixis's price / book?
Over 5 years (2020 to 2025), Exelixis's price / book has grown at a 6.5% compound annual growth rate (CAGR), from 3.7× to 5.1×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.